Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.
about
The pivotal role of mammalian target of rapamycin inhibition in the treatment of patients with neuroendocrine tumorsHow do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studiesJudicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and PerspectivesSystematic review reveals lack of quality in reporting health-related quality of life in patients with gastroenteropancreatic neuroendocrine tumoursSummary of emerging personalized medicine in neuroendocrine tumors: are we on track?Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement.New therapeutic approaches to metastatic gastroenteropancreatic neuroendocrine tumors: A glimpse into the future.Capecitabine and temozolomide in grade 1/2 neuroendocrine tumors: a Spanish multicenter experience.Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.Efficacy of peptide receptor radionuclide therapy with 177Lu-octreotate in metastatic pulmonary neuroendocrine tumors: a dual-centre analysis.Management Options for Advanced Low or Intermediate Grade Gastroenteropancreatic Neuroendocrine Tumors: Review of Recent Literature.Patient-Reported Burden of a Neuroendocrine Tumor (NET) Diagnosis: Results From the First Global Survey of Patients With NETs.Biologics in gastrointestinal and pancreatic neuroendocrine tumorsA Phase II Study of Everolimus Plus Oral Prednisone in Patients with Metastatic Renal Cell Cancer.Systematic Review and Meta-Analysis on the Role of Chemotherapy in Advanced and Metastatic Neuroendocrine Tumor (NET)Management of controversial gastroenteropancreatic neuroendocrine tumour clinical situations with somatostatin analogues: results of a Delphi questionnaire panel from the NETPraxis program.The MTH1 inhibitor TH588 demonstrates anti-tumoral effects alone and in combination with everolimus, 5-FU and gamma-irradiation in neuroendocrine tumor cells.Efficacy and Safety of Everolimus in Extrapancreatic Neuroendocrine Tumor: A Comprehensive Review of Literature.A phase II study of axitinib in advanced neuroendocrine tumors.BEZ235: When Promising Science Meets Clinical RealityRole of targeted agents in neuroendocrine tumors: Results from a meta-analysis.A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease managementGenes involved in angiogenesis and mTOR pathways are frequently mutated in Asian patients with pancreatic neuroendocrine tumors.Guidelines for the management of neuroendocrine tumours by the Brazilian gastrointestinal tumour groupPancreatic Neuroendocrine Neoplasms: Basic Biology, Current Treatment Strategies and Prospects for the Future.Refractory carcinoid syndrome: a review of treatment options.Resistance to mTORC1 Inhibitors in Cancer Therapy: From Kinase Mutations to Intratumoral Heterogeneity of Kinase ActivityCurrent understanding and approach to well differentiated lung neuroendocrine tumors: an update on classification and management.Emerging use of everolimus in the treatment of neuroendocrine tumors.A phase Ib study of everolimus combined with metformin for patients with advanced cancer.Patterns and Drivers of Costs for Neuroendocrine Tumor Care: A Comparative Population-Based Analysis.The underestimated role of somatostatin analogs in the NETTER-1 trial.Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States.The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models.Neuroendocrine tumors of the gastrointestinal tract and the role of cytotoxic chemotherapy.Predictive Markers of Response to Everolimus and Sunitinib in Neuroendocrine Tumors.The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society.Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives.Effects of the single and combined treatment with dopamine agonist, somatostatin analog and mTOR inhibitors in a human lung carcinoid cell line: an in vitro study.Treatment Strategies for Metastatic Neuroendocrine Tumors of the Gastrointestinal Tract.
P2860
Q26740374-BB0DA0D7-C6B9-4E26-B9AF-562795E37D1DQ26750748-26DB19FA-2D1E-4C6F-9B09-9C609DFB23E4Q28071388-D5A43E61-CDAF-4AD7-BCB6-A41E4DD2EC57Q28071978-EC98C518-E649-48EC-A6F1-5E60AF59B105Q28078610-D1F8A061-D666-4158-B51F-8F230EECAE90Q30249051-F0736F79-CA21-4762-AD48-0A093762170AQ30364864-2DED6615-0F27-4EA0-A58E-E749621B95B0Q33436462-FFBCEF17-EDBB-4443-AD1A-3689E6296256Q33438326-43B12762-4657-438E-A016-640899CBE5C1Q33700134-78A87A71-5F3B-4F14-B7FB-737090C08167Q33737587-FA545D7A-A039-4AAF-99C5-408774BDED3AQ33859561-1FC41C89-A177-4C2A-AED8-BA211A1481BDQ33895557-6B43B835-2E0D-4AE3-A660-829104388265Q33898884-1CF0D9FC-FA21-4072-9EE9-0F78E50C80B3Q36065003-964CE83E-D9E0-4A96-905E-EC7C0DA0DDC2Q36184629-82AB2A95-F2BF-491A-83F8-9F8D5C8CA571Q36380974-27A46722-9521-4970-89B7-5BA887F986FEQ37091117-02096A64-1C45-4DE8-B332-E8E371CE88D1Q37131421-7BC0FE1B-D3B7-4526-8871-FFBD3EC8D60EQ37242369-6EF646F5-49C1-4E5D-BB41-D00110030D09Q37282982-3F29CCB5-4624-4EBD-B0D2-1CD2CF517DABQ37302087-FD917A6B-CC08-4267-8B43-67978C2CCB68Q37513931-6A8FCF10-974D-4BEC-8B58-5F76C532C1B3Q37629658-CD5A2BF0-9FD2-4B35-A0A6-26B8CDC88B29Q37631597-EC8CF570-746B-4E79-A4E4-A084A7EEDB1BQ37632161-047E4FA2-7A3E-4B12-9181-E106649EEC6BQ37661161-151F6ACE-6D23-41F7-B590-BEC389D8321FQ37698605-BC95E372-C4FB-4046-A45B-6B3F61CC62EFQ38661603-B6802E3B-B2F0-4188-9DE9-D5411E8860FCQ38670844-67C5D83C-E9A7-4ED5-BF4C-E82B599BF7DBQ38684849-2B82CB32-FC6F-4DF4-8C4A-E4AA0AC9964EQ38685351-6CEBADDB-B51A-43C6-9720-8A5AAE14F7A8Q38690230-B554EF1B-F56A-443F-B8BE-248316BE5C38Q38695102-526B5A36-E7F2-43D8-9B92-5A633DFEFE17Q38711101-2361CC40-EC50-433D-BB98-37D1572473F7Q38716228-4616AF73-6704-45FB-AD31-664E7C61F25EQ38727852-B349FBB1-48D4-4A7A-9249-475A79131AECQ38730927-00AC15B2-076A-445B-AF38-E7053DE5F80CQ38743093-C68E4483-BD81-43A9-9DA0-57D5A977F5FAQ38746782-7F77E1DF-39FA-46B4-A21B-F9A7EF453062
P2860
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Everolimus for the treatment o ...... ebo-controlled, phase 3 study.
@en
type
label
Everolimus for the treatment o ...... ebo-controlled, phase 3 study.
@en
prefLabel
Everolimus for the treatment o ...... ebo-controlled, phase 3 study.
@en
P2093
P2860
P1433
P1476
Everolimus for the treatment o ...... cebo-controlled, phase 3 study
@en
P2093
Carlo Carnaghi
Carolin Sachs
Do-Youn Oh
Edward Wolin
Eric Van Cutsem
Gianfranco Delle Fave
Harald Lahner
James C Yao
Jiri Tomasek
Jonathan Strosberg
P2860
P304
P356
10.1016/S0140-6736(15)00817-X
P407
P50
P577
2015-12-17T00:00:00Z